Novo Nordisk Offers Discounted Wegovy Subscription Plan For US Patients To Compete With Eli Lilly

• Monthly prices for Wegovy injections range from $329 for three months to $249 for a year-long plan, compared to the usual $349.
• Comparatively, Eli Lilly's self-pay pricing for Zepbound starts at $299 per month for the 2.5 mg dose, rising to $399 for 5 mg, and $449 for 7.5 mg.
• The plan is currently available through telehealth platforms like Ro, WeightWatchers, and LifeMD.

Novo Nordisk (NVO) has announced a discounted subscription plan for U.S. patients paying out of pocket for its obesity drug Wegovy, in a bid to compete more effectively with Eli Lilly.

NVO shares were little changed in pre-market trading on Tuesday.

Savings of $600 - $1,200 Annually

Patients can save up to $600 per year on Wegovy pills and up to $1,200 per year on Wegovy injections with a 12-month subscription, Novo said. The plan, available through telehealth platforms like Ro, WeightWatchers, and LifeMD, allows eligible patients to choose three-, six-, or 12-month subscriptions, with bigger discounts for longer commitments.

Hims & Hers, Sesame, and other telehealth companies are expected to offer discounts soon.

“By providing predictable monthly pricing, multi-month options, and access through trusted telehealth providers, this program aims to support a more manageable way for people to stay on treatment and focus on achieving meaningful, sustainable weight loss outcomes,” said Ed Cinca, senior vice president, Marketing & Patient Solutions at Novo Nordisk.

Wegovy Pricing Breakdown

Monthly prices for Wegovy injections range from $329 for three months to $249 for a year-long plan, compared to the usual $349. The pill version is priced between $249 and $289 per month. 

Eli Lilly's self-pay pricing for Zepbound starts at $299 per month for the 2.5 mg dose, rising to $399 for 5 mg, $449 for 7.5 mg, and higher doses.

This comes just days after Hims and Hers launched a broad lineup of Novo Nordisk GLP-1 medications on its platform. Novo had earlier dropped its patent infringement lawsuit against Hims related to its blockbuster weight-loss drugs.

How Did Retail Traders React?

Retail sentiment on Stocktwits has remained in the ‘bearish’ territory for a month.

One user said that until the large institutions change their outlook on Novo, the stock will remain around $35. 

Another user said the stock’s valuation is “beyond cheap.”

NVO shares have declined by more than 30% so far this year.

For updates and corrections, email newsroom[at]stocktwits[dot]com.